ClearPoint Neuro
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
March 19, 2024 08:07 ET | ClearPoint Neuro, Inc.
ClearPoint Neuro's partner's completed BLA Submission for Upstaza™ would be first disease-modifying treatment for AADC Deficiency in the US.
2024 MDA Legacy Award for Achievement in Research
Muscular Dystrophy Association Announces Recipient of 2024 MDA Legacy Award for Achievement in Research, is Jeffrey Chamberlain, Ph.D., Leading Professor in Gene Therapy
January 30, 2024 09:59 ET | Muscular Dystrophy Association
New York, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Jeffrey Chamberlain, Ph.D., a leading professor in gene therapy focused on Duchenne muscular...
Kriya logo.jpg
Kriya Provides Update on Pipeline Progress Ahead of Company Presentation at 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024 09:00 ET | Kriya Therapeutics, Inc.
– Kriya anticipates up to 5 programs to enter clinic by the end of 2025 – – Current pipeline of gene therapies for common diseases spans three major therapeutics areas: ophthalmology, metabolic...
Kriya logo.jpg
Kriya Announces Gene Therapy Program for Thyroid Eye Disease
January 05, 2024 09:00 ET | Kriya Therapeutics, Inc.
– KRIYA-586 is designed to be a one-time treatment delivered by focal peribulbar injection, that encodes an antibody blocking the Insulin-Like Growth Factor 1 Receptor (IGF-1R), a clinically validated...
2018_DHC_logo_Color_Large.jpg
Dark Horse Consulting Group Announces Launching of DHC Asia Pacific, Hiring of John Ng as General Manager
November 13, 2023 16:20 ET | Dark Horse Consulting Group
Dark Horse Consulting Group Announces Launching of DHC Asia Pacific, Hiring of John Ng as General Manager
Kriya logo.jpg
Kriya Announces Exclusive License and Collaboration Agreement with Everads to Advance Gene Therapies for Prevalent Diseases in Ophthalmology Including Geographic Atrophy
September 27, 2023 08:30 ET | Kriya Therapeutics, Inc.
– Everads' next generation suprachoroidal delivery technology enables targeted drug delivery to the retina, which Kriya intends to use for multiple ophthalmology gene therapy product candidates – ...
2024 MDA Clinical & Scientific Conference
Registration Now Open for 2024 MDA Clinical & Scientific Conference, to Showcase Cutting Edge Research Advancements and Clinical Achievements in Neuromuscular Disease
August 09, 2023 10:35 ET | Muscular Dystrophy Association
New York, Aug. 09, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA), convener of the largest worldwide gathering of the neuromuscular disease community, announced today that...
ultragenyx-CMYK.png
Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
July 31, 2023 08:00 ET | Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced it has begun dosing the second dose-escalation cohort in its pivotal Phase 1/2/3...
2018_DHC_logo_Color_Large.jpg
Correction: Dark Horse Consulting Group Welcomes Growth Investment from WestView Capital Partners
October 04, 2022 09:21 ET | Dark Horse Consulting Group
Walnut Creek, CA; Boston, MA, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group ("DHC"), the leading global consultancy to the cell and gene therapy (“CGT”) industry, and WestView...
The Dark Horse Consulting Group logo contains the initials DHC, rendered in British Racing Green and with a profile of a horse's head within the "D"
Dark Horse Consulting Group Welcomes Growth Investment from WestView Capital Partners
October 04, 2022 08:12 ET | Dark Horse Consulting Group
Walnut City, CA; Boston, MA, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group ("DHC"), the leading global consultancy to the cell and gene therapy (“CGT”) industry, and WestView Capital...